

**INFORMATION DISCLOSURE
STATEMENT LIST**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		4550081	10-29-1985	Stocker	
		4530901	7-23-1985	Weissman	
		4440859	04-09-1984	Rutter	
		4582800	04-15-1986	Crowl	
		4677063	06-30-1987	Mark	
		4704362	11-03-1987	Itakura	
		4710463	12-01-1987	Murray	
		4766075	09-23-1988	Goeddel	
		4757006	07-12-1988	Toole	
		4810648	03-07-1989	Stalker	
		4837151	06-06-1989	Stocker	
		5356797	10-18-1994	Nielsen	
		5397697	03-14-1995	Lam	
		5210035	5-11-1993	Stocker	
		5643579	07-01-1997	Hung	
		6251406	06-26-2001	Haeffliger	
		6458368	10-01-2002	Haeffliger	
		6585975	01-07-2003	Kleanthous	
		6756042	6-29-2004	Feldman	
		6846667	01-25-2005	Crooke	

Examiner Signature:

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SHEET 2 OF 51

**INFORMATION DISCLOSURE
STATEMENT LIST**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		6936425	08-30-2005	Hensel	
		6951732	10-04-2005	Clarke	
		6984490	01-10-2006	Holden	
		7211264	05-01-2007	Feldman	
		7449178	11-11-2008	Crooke	
		20040203039	10-14-2004	Hensel	
		20060216309	09-28-2006	Holden	
		20080075739	03-27-2008	Hensel et al.	
		20080175866	07-24-2008	Holdon	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		WO 9220805	11-26-1992	PF Medicament		
		WO 9310246	05-27-1993	University of Texas		
		WO 9411024	05-26-1994	Univ. Minnesota		
		WO 9611708	04-25-1996	University of Texas		
		WO 9718225	05-22-1997	Gen. Hospital Corp.		
		WO 9806428	02-19-1998	UAB Research Foundation		

Examiner Signature:

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SHEET 3 OF 51

**INFORMATION DISCLOSURE
STATEMENT LIST**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD- YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		WO 9835562	08-20-1998	Merck & Co Inc.		
		EP 0889120	01-07-1999	Imp College Innovations		
		WO 9945120	09-01-1999	Biotech&Biolog Scien Res		
		WO 9901473	01-14-1999	Imp College Innovations		
		WO 0014240	03-16-2000	Creatogen Biosciences		
		WO 03044047	05-30-2003	London School of Hygiene		
		WO 0132697	05-10-2001	Unite de Rech en Biol Molecu		
		WO 0185772	11-15-2001	Microscience Ltd.		

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		ABAEV, et al. (1997) "Stable expresion of heterologous proteins in Salmonella: Problems and approaches to their designing," Vestn. Ross Akad Med Nauk 6:48-52 ABSTRACT ONLY	No
		AGRAWAL and GOODCHILD (1987) "Oligodeoxynucleotide methylphosphonate: synthesis and enzymatic degradation." Tetrahedron Letters, 28:3536-3542	
		AGRAWAL and TANG (1990) "Efficient synthesis of oligoribonucleotide and its phosphorothioate analogue using H-Phosphonate Approach," Tetradhedron Letters, 31:7541-7544	
		AGRAWAL (1998) "Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus," PNAS 85:7079-7083	
		AGRAWAL (1990) "Site-specific excision from RNA by RNase H and mixed phosphate-backbone oligodeoxyribonucleotides." PNAS 87:1401-1405	
		AGRAWAL et al. (1991) "Pharmacokinetics, biodistribution and stability of oligodeoxynucleotide phosphorothioates in mice," PNAS, 88:7595-7599	

Examiner Signature:		Date Considered	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

**INFORMATION DISCLOSURE
STATEMENT LIST**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		ALLAOUI, et al. (1993) "MxiD, an outer membrane protein necessary for the secretion of Shigella flexneri lpa invasins," Mol. Microbiol., 7:59-68	
		ALTMAYER, et al. (1993) "Cloning and molecular characterization of gene involved in Salmonella adherence and invasion of cultured epithelial cells," Mol. Microbiol., 7:89-98.	
		ANDREWS and MAURELLI (1992) "MxiA of Shigella flexneria 2a, which facilitates export of invasion plasmid antigens encodes a homol of low-calcium-response protein LcrD, of Yersinia pestis," Infect. Immun. 60:3287-3295	
		BACHMAN (1990) "Linkage map of E. coli K-12," Micro. Rev. 54:130-197.	
		"BAJAJ, et al. (1996) "Co-ordinate regulation of Salmonella typhimurium invasion genes by environmental and regulatory factor is mediated by control of expression," Mol. Microbiol. 18:715-727	
		BAJAJ, et al. (1995) "'hilA is notvel ompR/toxR family member that activates the expression of Salmonella typhimurium invasion genes." Mol. Microbiol. 18:715-727.	
		BANNWARTH (1988) "Solid-phase synthesis of oligodeoxynucleotides containing phosphoramidate internucleotide linkages and their specific chemical cleavage," Helv. Chim. Acta. 71:1517-1527	
		BAUDRY, et al. (1988) "Nucleotide sequence of the invasion plasmid antigen B and C genes (ipaB and ipaC) of Shigella flexneri," Microb. Pathog. 4:345-357	
		BENSON and GOLDMAN (1992) "Rapid mapping in Salmonella typhimurium with Mud-P22 prophages," J. Bacteriol. 175:1673-1681	
		BODDIKCE, et al. (2006) "Signature-tagged mutagenesis of Klebsiella pneumoniae to identify genes that influence biofilm formation on extracellular matrix material," Infect. Immun. 74:4590-4597	

Examiner Signature:	Date Considered
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		BOGDANOVE, et al. (1996) "Unified nomenclature for broadly conserved hrp genes of phytopathogenic bacteria," Mol. Microbiol. 20:681-683	
		BOURGOGNE, et al. (1998) "Salmonella abortusovus strain RV6, new vaccinal vehicle for small ruminants," Vet. Microbiol. 61:199-213 ABSTRACT ONLY	
		CARDENAS, et al. (1994) "Influence of strain viability and antigen done on the use of attenuated mutants of Salmonella as vaccine carriers," Vaccine 12:883-840	
		CARDENAS, et al. (1993) "Stability, immunogenicity and expression of foreign antigens in bacterial vaccine vectors," Vaccine 11:122-125 ABSTRACT ONLY	
		CARDENAS, et al. (1992) "Oral administration using live attenuated Salmonella spp. as carriers of foreign antigens," Clin. Microbiol. Rev. 5:328-342	
		CATTOZZO, et al. (1997) "Expression of immunogenicity of V3 loop epitopes of HIV isolates SC and WMJ2, inserted in Salmonella flagellin," J. Biotechnol. 56:191-203 ABSTRACT ONLY	
		CHABALGOITY, et al. (1996) "A Salmonella typhimurium htrA live vaccine expressing multiple copies of a peptide comprising amino acids 8-23 of herpes simplex virus glycoprotein D as a genetic fusion to tetanus toxin fragment C protects mice from herpes simplex virus infection," Mol. Microbiol. 19:791-801	
		CHACON, et al. (1996) "Heterologous expression of the citric glutathione peroxidase of lymphatic filariae in an attenuated vaccine strain of Salmonella typhimurium abrogates H-2 restriction of specific antibody response," Parasite Immunol. 18:307-316 ABSTRACT ONLY	
		CHANG, et al. (1978) "Construction and characterization of amplifiable multicopy DNA cloning vehicles derived from the P15A cryptic miniplasmid" J. Bacteriol. 134:1141-1156	

Examiner Signature:

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		CHARLES, et al. (1990) "Gene expression an the development of live enteric vaccines," Trends Biotechnol. 8:117-121 ABSTRACT ONLY	
		CHATFIELD, et al (1992) "Construction of a genetically defined Salmonella typhi Ty2 aro A, aroC mutain for the engineering of a candidate oral typhoid-tetanus vaccine," Vaccine 10:53-60	
		CHATFIELD, et al. (1994) "The use of live attenuated Salmonella for oral vaccination," Dev. Biol. Stand. 82:35-42	
		CHATFIELD, et al. (1993) "The development of oral vaccines based on live attenuated <i>Salmonella</i> strains," FEMS Immunol. Med. Microbiol. 7:1-7	
		CHATFIELD, et al. (1995) "The development of oral vaccines against parasitic diseases utilizing live attenuated <i>Salmonella</i> ," Paristology 110Suppl.:S17-S24	
		CHATFIELD, et al. (1989) "Live Salmonella vaccines and carriers of foreign antigenic determinants," Vaccine 7:495-498	
		CIRILLO, et al. (1995) "Bacterial vaccine vectors and bacillus Calmette-Guerin," Clin. Infect. Dis. 30:1001-1009.	
		CLEMENS (1987) "Use of attenuated mutants of Salmonella as carriers for delivery of heterologous antigens to the secretory immune system," Pathol. Immunopathol. Res. 6:137-146	
		CLEMENTS (1990) "Vaccines against enterotoxigenic bacterial pathogens based on hybrid Salmonella that express heterologous antigens," Res. Microbiol. 141:981-993. ABSTRACT ONLY	

Examiner Signature:		Date Considered	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		COHEN, et al. (1990) "Microbial isopenicillin N synthase genes: structure, function, diversity and evolution," Trends in Biotechnol. 8:105-111	
		COLLAZO, et al. (1995) "Functional analysis of the Salmonella typhimurium invasion genes invI and invJ and identification of a target of the protein secretion apparatus encoded in the inv. locus," Mol. Microbiol. 15:25-38	
		COSSTICK and VYLE (1989) "Solid phase synthesis of oligonucleotides containing 3'-thioymidase," Tetrahedron Letters, 30:4693:4696	
		COVONE, et al. (1998) "Levels of expression and immunogenicity of attenuated Salmonella enterica servar typhimurium strains expression Escherichia coli mutant heat-labile enterotoxin," Infect. Immun. 66:224-231	
		COYNAULT, et al. (1992) "Growth phase and SpvR regulation of transcription in Salmonella typhimurium spvANC virulence genes," Microb. Pathog. 13:133-143. ABSTRACT ONLY	
		CURTISS, et al. (1990) "Stabilization of recombinant avirulent vaccine strains in vivo," Res. Microbiol. 141:797-805. ABSTRACT ONLY	
		DAVIDSON, et al. (1995) "Lung disease in the cystic fibrosis mouse exposed to bacterial pathogens," Nat. Genet. 9:351-357	
		DE LORENZO, et al. (1990) "Mino-Tn5 transposon derivatives for insertion mutagenesis promoter probing, and chromosomal insertion of cloned DNA in gram-negative eubacteria," J. Bacteriol. 172:6568-6572	
		DE LORENZO and TIMIS (1994) "Analysis of stable phenotypes in gram negative bacteria with Tn5 and Tn10-derived minitransposons," Methods Enzymol. 235:386-405	

Examiner Signature:

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		DEGROOTE, et al (1997) "Periplasmic superoxide dismutase protects Salmonella from products of phagocyte NADPH-oxidase and nitric oxide synthase," PNAS 94:13997-14001	
		DEIWEICK, et al. (1999) "Environmental regulation of Salmonella pathogenicity island 2 gene expression," Mol. Microbiol. 31:1759-1773	
		DIEDERICH, et at. (2000) "In search for specific inhibitors of human 11beta-hydroxysteroid-dehydrogenases (11beta-HSDs): Chenodeoxycholic acid selectivity inhibits 11beta-HSD-1" Eur. J. Endocrinol. 142:200-207	
		DEIWICK and HENSEL (1999) "Regulation of virulence genes by environmental signal in Salmonella typhimurium electrophoresis," 20:813-817. ABSTRACT ONLY	
		DOGGETT, et al. (1993) "Immune response to Streptococcus sobrinus surface protein antigen A expressed by recombinant Salmonella typhimurium," Infect. Immun. 61:1859-1866	
		DONNENBERG, et al. (1991) "Construction of an eae deletion mutant of enteropathogenic Escherichia coli using a positive-selection suicide vector," Infect. Immunol. 59:4310-4317	
		DOUGAN, et al. (1989) "Live bacterial vaccines and their application as carrier for foreign antigen," Adv. in Vet. Sci. and Comp. Med. 33:277-300	
		DOUGAN, et al. (1987) "Live oral Salmonella vaccines: potential use of attenuated strains as carriers of heterologous antigens to the immune system," Parasite Immunol. 9:151-160	
		EICHELBERG, et al. (1994) "Molecular and functional characterization of the Salmonella typhimurium invasion genes invB and invC: homology of invC to the FOF1 ATPase family of proteins," J. Bacteriol. 176:4501-4510	

Examiner Signature:	Date Considered
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		ELLIOT, et al. (1998) "The complete sequence of the locus of enterocyte affacement (LEE) from enteropathogenic Escherichia coli E2348/49," Mol. Microbiol. 28:1-4	
		EVERST, et al. (1995) "Expression of LacZ from the hrtA, nirB and groE promoters in a Salmonella vaccine strain: influence of growth in mammalian cells," FEMS Microbiol. Letters 126:97-101	
		FAYOLE, et al. (1994) "Genetic control of antibody responses induced against an antigen delivered by recombinant attenuated Salmonella typhimurium," Infect. Immun. 62:4310-4319	
		FIELDS, et al. (1986) "Mutants of Salmonella typhimurium that cannot survive within the macrophage are invirulent," PNAS 83:5189-5193	
		FIERER, et al. (1993) "Expression of the Salmonella virulence plasmid gene spvB in cultured macrophages and nonphagocytic cells," Infect. Immun. 61:5231-5236	
		FINLAY, et al. (1991) "Cytoskeletal rearrangements accompanying Salmonella entry into epithelial cells," 99:283-296	
		FINLAY (1994) "Molecular and cellular mechanisms of Salmonella pathogenesis" Curr. Top. Microbiol. Immunol. 192:163-185	
		FOULONGNE, et al. (2000) "Identification of Brucella suis genes affecting intracellular survival in an in vitro human macrophage infection model by signature-tagged transposon mutagenesis," Infect. Immun. 68:1297-1303	
		FORSBERG, et al. (1994) "Use of transcriptional fusions to monitor gene expression: a cautionary tale," J. Bacteriol. 176:2128-2132	

Examiner Signature:		Date Considered	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		FOUTS, et al. (1995) "Construction and immunogenicity of Salmonella typhimurium vaccine vectors that express HIV-1 gp120," Vaccine 13:1697-1705. ABSTRACT ONLY	
		FOUTS, et al. (1995) "Construction and characterization of Salmonella-typhi based human immunodeficiency virus type 1 vector vaccine," Vaccine 13:561-569. ABSTRACT ONLY	
		FRANCIS et al. (1992) Morphological and cytoskeletal changes in epithelial cells occur immediately upon interaction with Salmonella typhimurium grown under low-oxygen conditions," Mol. Microbiol. 6:3077-3087	
		GENTSCHEV, et al. (1998) "Delivery of the p67 sporozite antigen Theileria parva by using recombinant Salmonella dublin: secretion of the product enhances specific antibody responses in cattle," Infect. Immun. 66:2060-2064	
		GINNOCHIO, et al. (1992) "Identification and molecular characterization of a Salmonella typhimurium gene involved in triggering the internalization of Salmonella into cultured epithelial cells," PNAS 89:1575-5980	
		GINNOCCHIO, et al. (1994) "Contact with epithelial cells induces the formation of surface appendages on Salmonella typhimurium," Cell 76:717-724	
		GUILLOBEL, et al. (1998) "Immunization against the colonization factor antigen I of enterotoxigenic Escherichia coli by administration of a bivalent Salmonella typhimurium aroA strain," Braz. J. Med. Biol. Res. 31:545-554. ABSTRACT ONLY	
		GUNN and MILLER (1996) "PhoP-PhoQ activates transcription of pmrAB, encoding a two-component regulatory system involved in Salmonella typhimurium antimicrobial peptide resistance," J. Bacteriol. 178:6857-6864	

Examiner Signature:		Date Considered	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		GUY, et al. (2000) "Aggregation of host endosomes by Salmonella requires SPI2 translocation of SseGF and involves SpvR and the fms-aroE intergenic region," Mol. Microbiol. 37:1417-1435. ABSTRACT ONLY	
		HADDAD, et al. (1995) "Surface display compared to periplasmic expression of a malarial antigen in Salmonella typhimurium and its implications for immunogenicity," FEMS Immunol. Med. Microbiol. 12:175-186. ABSTRACT ONLY	
		HAHN, et al. (1998) A Salmonella typhimurium strain genetically engineered to secrete a bioactive human interleukin (hIL)-6 via the Escherichia coli hemolysin secretion apparatus," FEMS Immunol. Med. Microbiol. 20:111-119. ABSTRACT ONLY	
		HAKANSSON, et al. (1996) "The YoB protein of Yersinia pseudotuberculosis is essential for the translocation of Yop effector proteins across the target cell plasma membrane and displays a contact-dependent membrane disrupting activity," EMBO J. 15:5812-5823	
		HAROKOPAKIS et al. (1997) "Mucosal immunogenicity of a recombinant Salmonella typhimurium-cloned heterologous antigen in the absence or presence of co-expressed cholera toxin A2 and B subunits," Infect. Immun. 65:1445-1454	
		HAUSER, et al. (1998) "Defects in type III secretion correlate with internalization of Pseudomonas aeruginosa by epithelial cells," Infect. Immun. 66:1413-1420	
		HAVAARSTEIN, et al. (1995) "An unmodified heptadecapeptide pheromone induces competence for genetic transformation in Streptococcus pneumoniae," PNAS 92:11140-11144	
		HE, et al. (2000) "Function of human brain short chain L-3 hydroxyl coenzyme A dehydrogenase in androgen metabolism," Biochemica Et. Biophysica Acta:1484:267-277	

Examiner Signature:	Date Considered
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		HEITHOFF, et al. (1999) "An essential role for DNA adenine methylation in bacterial virulence," Science 284:967-970	
		HENSEL and HOLDEN (1996) "Molecular genetic approaches for the study of virulence in both pathogenic bacteria and fungi," Microbiol. 142:1049-1058	
		HERRERO, et al. (1990) "Transposon vectors containing non-antibiotic resistance selection markers for cloning and stable chromosomal insertion of foreign genes in gram negative bacteria," J. Bacteriol. 172:6557-6567	
		HESS, et al. (1997) "Protection against murine listeriosis by an attenuated recombinant Salmonella typhimurium vaccine strain that secretes the naturally somatic antigen superoxide dismutase," Infect. Immun. 65:1286-1292	
		HESS, et al. (1995) "Listeria monocytogenes p60 supports host cell invasion by and in vivo survival of attenuated Salmonella typhimurium," Infect. Immun. 63:2047-2053	
		HESS, et al. (1996) "Superior efficacy of secreted over somatic antigen display in recombinant Salmonella vaccine induced protection against listeriosis," PNAS 93:1458-1463	
		HESS, et al. (1997) "Modulation of antigen display by attenuated Salmonella typhimurium strains and its impact on protective immunity against listeriosis," Behring Inst. Mitt. 160-171	
		HIRAKATA, et al. (1992) "Efficacy of erythromycin lactobionate for treating Pseudomonas aeruginosa bacteremia in mice," Antimicrob. Agents Chemother. 36:1198-1203	
		HOFFMAN and STOFFEL (1993) "TMbase-a database of membrane spanning protein segments," Biol. Chem. Hoppe-Seyler 347:166	

Examiner Signature:		Date Considered	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		HOHMANN, et al. (1995) "Macrophage-inducible expression of a model antigen in Salmonella typhimurium enhances immunogenicity," PNAS 92:2904-2908	
		HOHMANN, et al. (1996) "Evaluation of phoP/phoQ-deleted aroA-deleted live oral Salmonella typhi vaccine strain in human volunteers," Vaccine 14:19-24	
		HOLDEN, et al. (1989) "Mutation in heat-regulated hsp70 gene of Ustilago maydis," EMBO J. 8:1927-1934	
		HOLTEL, et al. (1992) "Upstream binding sequences of the XylR activator protein and integration host factor in the xylS gene promoter region of the Pseudomonas TOL plasmid," Nucl. Acid Res. 20:1755-1762	
		HONE, et al. (1988) "A chromosomal integration system for stabilization of heterologous genes in Salmonella based vaccine strains," Microb. Pathog. 5:407-418. ABSTRACT ONLY	
		HORMAECHE, et al. (1996) "Protection against oral challenge three months after i.v. immunization of BALB/c mice with live Aro Salmonella typhimurium and Salmonella enteritidis vaccines is serotype (species)-dependent and only partially determined by the main LPS O antigen," Vaccine 14:251-259. ABSTRACT ONLY	
		HORMAECHE, et al. (1991) "Live attenuated Salmonella vaccines and their potential as oral combined vaccines carrying heterologous antigens," J. Immunol. 142:113-120. ABSTRACT ONLY	
		HUECK (1998) "Type III protein secretion systems in bacterial pathogens of animals and plants," Microbiol. Mol. Biol. Rev. 62:379-433	
		HUECK, et al. (1995) "Salmonella typhimurium secreted invasion determinants are homologous to Shigella lpa proteins," Mol. Microbiol. 18:479-490	

Examiner Signature:

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		JAGER, et al. (1988) "Oligonucleotide N-alkylphosphoramidates: synthesis and binding to polynucleotides," Biochemistry 20:7237-7246	
		JANSSEN, et al. (1995) "Induction of the phoE promoter upon invasion of Salmonella typhimurium into eukaryotic cells," Microb. Pathog. 19:193-201. ABSTRACT ONLY	
		JORNVALL, et al. (1995) "Short chain dehydrogenases/reductases (SDR)" Biochemistry 34:6003-6013	
		JORNVALL, et al. (1999) "SDR and MDR: Completed genome sequences show these protein families to be large, of old origin and complex nature," FEBS Letters 445:261-264	
		KANIGA, et al. (1995) "Homologs of the Shigella Ipa and IpC invasins are required for Salmonella typhimurium entry into cultured epithelial cells," J. Bacteriol. 177:3965-3971	
		KANIGA, et al. (1994) "The Salmonella typhimurium invasion genes invF and invG encode homologs of the AraC and PulD family of proteins," Mol. Microbiol. 13L555-568	
		KAREM, et al. (1996) "Cytokine expression in the gut associated lymphoid tissue after oral administration of attenuated Salmonella vaccine strains," Vaccine 14:1495-1502. ABSTRACT ONLY	
		KIRSCH and DI DOMENICO (1993) "The discovery of natural products with a therapeutic potential," V.P. Gallo, Ed. Chapter 6, pages 1770221, Butterworth, V.K.	
		KRUL, et al. (1996) "Induction of an antibody response in mice against human papilloma virus (HPV) type 16 after immunization with HPV recombinant Salmonella strains," Cancer Immunol. 43:44-48	

Examiner Signature:		Date Considered	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		KUWAJIA, et al. (1989) "Export of N-terminal fragment of Escherichia coli flagellin by a flagellum-specific pathway," PNAS, 86:4953-4957	
		LAEMMLI (1970) "Cleavage of structural proteins during the assembly of the head of bacteriophage T4," Nature 227:680-685	
		LEARY, et al. (1997) "Expression of an F1/V fusion protein in attenuated Salmonella typhimurium and protection of mice against plague," Microb. Pathog. 23:167-179. ABSTRACT ONLY	
		LEE, et al. (1992) "Identification of a Salmonella typhimurium invasion locus by selection for hyperinvasive mutants," PNAS 89:1847-1851	
		LEITER, et al. (1990) "Inhibition of influenza virus replication by phosphorothioate oligodeoxynucleotides," PNAS 87:3430-3434	
		LENZ, et al. (2000) "Chemical ligands, genomics and drug delivery," Drug Discovery Today 5:145-156	
		LEVINE, et al. (1996) "Attenuated Salmonella as live oral vaccines against typhoid fever and as live vectors." J. Biotechnol. 44(1-3):193-196	
		LILJEVIST, et al. (1996) "A novel expression system for Salmonella typhimurium, allowing high production levels, product secretion and efficient recovery," Biochem. Biophys. Res. Com. 218:356-359. ABSTRACT ONLY	
		LINGBERG (1995) "The history of live bacterial vaccines," Dev. Biol. Stand. 84:211-219. ABSTRACT ONLY	

Examiner Signature:

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		LI, et al. (1995) "Relationship between evolutionary rate and cellular location among the Inv/Spa invasion proteins of Salmonella enterica," PNAS 92:7252-7256	
		LO-MAN, et al. (1996) "Control by H-2 genes of the Th1 response induced against foreign antigen expressed by attenuated Salmonella typhimurium," Infect. Immun. 64:4424-4432	
		LOWE, et al. (1999) "Characterization of candidate live oral Salmonella typhi vaccine strains harboring defined mutations in aroA, aroC and htrA" Infect. Imm. 67:700-707	
		MACNAB (1996) "Flagella and motility in Escherichia coli and Salmonella: cellular and molecular biology," F.C. Neidardt, et al. (eds.) Washington, D.C.:ASM Press: 123-145	
		MASKELL, et al. (1987) "Salmonella typhimurium aroA mutants as carriers of Escherichia coli heat labile enterotoxin B subunit to the murine secretory and systemic immune systems," Microb. Pathog. 2:2211-221. ABSTRACT ONLY	
		MAURER, et al. (1984) "Functional interchangeability of DNA replication genes in Salmonella typhimurium and Escherichia coli demonstrated by a general complementation procedure," Genetics 108:1-23	
		MCSORLEY, et al. (1997) "Vaccine efficacy of Salmonella strains expressing glycoprotein 63 with different promoters," Infect. Immun. 65:171-178	
		MICHIELS, et al. (1991) "Analysis of virC, an operon involved in the secretion of Ypo proteins by Yersinia enterocolitica," J. Bacteriol. 173:4994-5009	
		MILICH, et al. (1995) "The hepatitis nucleocapsid as a vaccine carrier moiety," Ann. NY Acad. Sci. 754:187-201. ABSTRACT ONLY	

Examiner Signature:	Date Considered
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SHEET 17 OF 51

**INFORMATION DISCLOSURE
STATEMENT LIST**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		MILLER and MEKALANOS (1998) "A novel suicide vector and its use in construction of inversion mutations: osmoregulation of outer membrane proteins and virulence determinants in <i>Vibrio cholerae</i> requires ToxR," J Bacteriol. 170:2575-2593	
		MILLER et al. (1993) "The PhoP virulence regulon and live oral <i>Salmonella</i> vaccines," Vaccine 11:122-125	
		MINAMINO, et al (1999) "Components of the <i>Salmonella</i> flagellar export apparatus and classification of export substrates," J. Bacteriol. 181:1388-1394	
		MIRAS, et al. (1995) "Nucleotide sequence of <i>iagA</i> and <i>iagB</i> genes involved in invasion of HeLa cells by <i>Salmonella enterica</i> subsp. <i>Enterica</i> Ser. Typhi" Res. Microbiol. 146:17-20	
		MONACK, et al. (1996) "Salmonella typhimurium invasion induces apoptosis in infected macrophages," PNAS 93:9833-9838	
		NEWTON, et al. (1995) "Studies of the anaerobically induced promoter <i>pnrB</i> and the improved expression of bacterial antigens" 146:193-202	
		NIELSON, et al. (1998) "Synthesis and characterization of dinucleoside phosphorodithioates," Tetrahedron Letters, 29:2911-2914	
		OCALLAGHAN and CHARBIT (1990) "High efficiency transformation of <i>Salmonella typhimurium</i> and <i>Salmonella typhi</i> by electroporation," Mol. Gen. Genet. 223:156-158	
		OBEYSEKERE et al (1998) "Serines at the active site of 11 beta-hydroxysteroid dehydrogenase type I determine the rate of catalysis" Biochem. Biophys. Res. Commun. 250:469-473	

Examiner Signature:	Date Considered
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

**INFORMATION DISCLOSURE
STATEMENT LIST**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		OHARA, et al. (1989) "Direct genomic sequencing of bacterial DNA: the pyruvate kinase I gene of Escherichia coli," PNAS 86:6883-6887	
		OKAHASHI, et al. (1996) "Oral immunization of interleukin-4 (IL-4) knockout mice with a recombinant Salmonell strain or cholera toxin reveals CD4+ Th2 cells producing IL-6 and IL-10 are associated with mucosal immunoglobulin A responses," Infect. Immun. 64:1516-1525	
		OPPERMAN, et al. (1997) "Structure function relationships of SDR hydroxysteroid dehydrogenases," Advances in Exp. Med. and Biol. 414:403-415	
		ORR, et al. (1999) "Expression and immunogenicity of a mutant diphtheria toxin molecule, CRM197, and its fragments in Salmonella typhi vaccine strain CVD 908-htrA" Infect. Immun. 67:4290-4294	
		PALLEN, et al. (1997) "Coiled-coil domains in proteins secreted by type III secretion systems," Mol. Microbiol. 25:423-425	
		PEARCE, et al (1993) "Genetic identification of exported proteins in Streptococcus pneumoniae," Mol. Microbiol. 9:1037-1050	
		PERLMAN and FREEDMAN (1971) "Experimental endocarditis. II Staphylococcal infection of the aortic valve following placement of polyethylene catheter in the left side of the heart." Yale J. Biol. Med. 44:203-213	
		PLANO, et al. (1991) "LcrD, a membrane-bound reegulator of the Yersinia pestis low-calcium response," J. Bacteriol. 173:7293-7303	
		POZZA, et al.. (1998) "Construction and characterization of Salmonella typhimurium aroA simultaneously expressing the five pertussis toxin subunits," Vaccine 16:522-529. ABSTRACT ONLY	

Examiner Signature:

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SHEET 19 OF 51

**INFORMATION DISCLOSURE
STATEMENT LIST**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		RALPH, et al. (1975) "Reticulum cell sarcoma: and effector cell in antibody-dependent cell-mediated immunity," J. Immunol. 114:898-905	
		REED and MUENCH (1938) "A simple method of estimating fifty per cent end points," Am J. Hyg. 27:493-497	
		RHEN, et al. (1993) "Transcriptional regulation of Salmonella enterica virulence plasmid genes in cultured macrophages," Mol. Microbiol. 10:45-56. ABSTRACT ONLY	
		RONSON, et al. (1987) "Conserved domains in bacterial regulatory proteins that respond to environmental stimuli," Cell 49:579-581	
		ROY and COLEMAN (1994) "Mutations in firA, encoding the second acyltransferase in lipopolysaccharide biosynthesis, affect multiple steps in lipopolysaccharide biosynthesis," 176:1639-1646	
		SAIKI et al. (1988) "Primer directed enzymatic amplification of DNA with a thermostable DNA polymerase," Science 242:1503-1506	
		SALMOND and REEVES (1993) "Membrane traffic wardens and protein secretion in gram negative bacteria," Trends in Biochem. Sci. 18:7-12	
		SANDERSON, et al. (1995) "Genetic map of Salmonella typhimurium, edition VIII," Microbiol. Rev. 59:241-303	
		SANGER, et al. (1977) "DNA sequence with chain terminating inhibitors," PNAS 74:5463-5467	

Examiner Signature:		Date Considered	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		SARIN, et al. (1988) "Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates," PNAS 85:7448-7451	
		SASAKAWA, et al. (1993) "Eight genes in region 5 that form an operon are essential for invasion of epithelial cells by Shigella flexneria 2a," J. Bacteriol. 175:2334-2346	
		SCHMITT et al. (1996) "The attenuated phenotype of a Salmonella typhimurium flgM mutant is related to expression of FlhC flagellin," J. Bacteriol. 178:2911-2915	
		SCHODEL, et al. (1990) "Hepatitis B Virus Nucleocapsid/pre-S2 fusion proteins expressed in attenuated Salmonella for oral vaccination" J. Immunol. 145:4317-4321	
		SCHODEL (1990) "Oral vaccination using recombinant bacteria," Semin. Immunol. 12:341-349	
		SHAW et al. (1991) "Modified deoxyoligonucleotides stable to exonuclease degradation in serum," Nucleic Acids Res. 19:747-750	
		SIGWART, et al. (1989) "Effect of purA mutation on efficacy of Salmonella live-vaccine vectors," Infect. Immun. 57:1858-1861	
		SKORUPSKI and TAYLOR (1996) "Positive selection vectors for allelic exchange," Gene 169:47-52	
		STRUGNELL et al (1990) "Stable expression of foreign antigens from the chromosome of Salmonella typhimurium vaccine strains," Gene 88:57-63. ABSTRACT ONLY	
		STRUGNELL et al. (1992) "Characterization of a Salmonella typhimurium aro vaccine strain expressing the p69 antigen of Bordetella pertussis," Infect. Immun. 60:3994-4002	

Examiner Signature:	Date Considered
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		SU et al. (1992) "Extracellular export of Shiga toxin B-subunit haemolysin A (C-terminus) fusion proteins expressed in Salmonella typhimurium aro-A mutant and stimulation of B-subunit specific antibody responses," Microb. Pathog. 13:465-476. ABSTRACT ONLY	
		SULLIVAN et al (1993) "Evaluation of the efficacy of ciprofloxacin against Streptococcus pneumoniae by using a mouse protection model," Antimicrob. Agents Chemother. 37:234-239	
		TACKET et al. (1990) "Safety and immunogenicity, and efficacy against cholera challenge in humans of a typhoid-cholera hybrid vaccine derived from Salmonella typhi21a" Infect. Immun. 58:1620-1627	
		TACKET et al. (1997) "Safely and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system," Infect. Immun. 65:3381-3385	
		TAKEUCHI (1967) "Electron microscope studies of experimental Salmonella infection. I. Penetration into the intestinal epithelium by Salmonella typhimurium," Am. J. Pathol. 50:109-136	
		TANG et al. (1993) "Self-stabilized antisense oligodeoxynucleotide phosphorothioates: properties and anti-HIV activity," Nucleic Acids Res. 21:2729-2735	
		TIJHAAR et al. (1997) "Induction of feline immunodeficiency virus specific antibodies in cats with an attenuated Salmonella strain expressing the Gag protein," Vaccine 15:587-596	
		TIJHAAR et al. (1997) "Salmonella typhimurium aroA recombinants and immune-stimulating complexes as vaccine candidates for feline immunodeficiency virus," J. Gen. Virol. 46:129-138	
		UZNANSKI et al. (1987) "Deoxyribonucleoside 3'-phosphordiamidites as substrates for solid supported synthesis of oligodeoxyribonucleotides," Tetrahedron Letters 28:3401-3404	

Examiner Signature:	Date Considered
---------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

**INFORMATION DISCLOSURE
STATEMENT LIST**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		VALENTINE et al. (1996) "Induction of SIV capsid specific CTL and mucosal sIgA in mice immunized with recombinant S. typhimurium aroA mutant," Vaccine 14:138-146	
		VAN GIJSEGEM et al (1993) "Conservation of secretion pathways for pathogenicity determinants of plant and animal bacteria," Trends Microbiol. 1:175-180	
		VEBER et al. (1993) "Correlation between macrolide lung pharmacokinetics and therapeutic efficacy in a mouse model of pneumococcal pneumonia," J. Antimicrob. Chemother. 32:473-483	
		VENKATESAN et al. (1992) "Surface presentation of Shigella flexneri invasion plasmid antigens requires the products of the spa locus," J. Bacteriol. 174:1990-2001	
		VERMA et al. (1995) "Induction of a cellular immune response to a defined T cell epitope as an insert in the flagellin of a live vaccine strain of Salmonella," Vaccine 13:235-234. ABSTRACT ONLY	
		VILLAFANE et al. (1987) "Replication control genes of plasmid pE194," J. Bacteriol. 169:4822-4829	
		VIRET et al. (1993) "Molecular cloning and characterization of the genetic determinants that express the complete Shigella serotype D (shigella sonnei) lipopolysaccharide in heterologous live attenuated vaccine strains." Mol. Microbiol. 7:239-252. ABSTRACT ONLY	
		WANG et al, (2006) "Application of signature tagged mutagenesis to the study of Erwinia amylovora" FEMS Microbiol. Lett. 265:164-171	
		WATTIAU et al. (1994) "Individual chaperones required for Yop secretion by Wattiau et al. (1994) "Individual chaperones required for Yop secretion by Yersinia" PNAS 91:10493-10497	

Examiner Signature:	Date Considered
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		WHITMAN et al (1993) "Antibiotic treatment of experimental endocarditis due to vancomycin- and ampicillin-resistant Enterococcus faecium," Antimicrob. Agents Chemother. 37:2069-2073	
		WHITTLE et al. (1997) "Immune response to a Murray Valley encephalitis virus epitope expressed in the flagellin of an attenuated strain of Salmonella," J. Med. Microbiol. 46:129-138	
		WHITTLE AND VERMA (1997) "The immune response to a B-cell epitope delivered by Salmonella is enhanced by prior immunological experience," Vaccine 15:1737-1740. ABSTRACT ONLY	
		WIRTH et al. (1986) "Highly efficient protoplast transformation system for Streptococcus faecalis and a new Escherichia coli-S. Faecalis shuttle vector," J. Bacteriol. 165:831-836	
		WOODS et al. (1982) "Contribution of toxin A and elastase to virulence of Pseudomonas aeruginosa in chronic lung infections of rats," Infect. Immun. 36:1223-1228	
		YAN et al. (1996) "Mixed population approach for vaccination with live recombinant Salmonella strains." J. Biotechnol. 44:197-201. ABSTRACT ONLY	
		YANCEY (1993) "Recent advances in bovine vaccine technology," J. Dairy Sci. 76:2418-2436	
		YANG et al., (1990) "Oral Salmonella typhimurium (AroA-) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis," J. Immunol. 145:2281-2285. ABSTRACT ONLY	
		YANISCH-PERRON et al. (1985) "Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors." Gene 33:103-119	

Examiner Signature:	Date Considered
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SHEET 24 OF 51

**INFORMATION DISCLOSURE
STATEMENT LIST**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		YOUDERAIN et al. (1988) "Packaging specific segments of the Salmonella chromosome locked-in Mud-P22 prophages," Genetics, 118:581-592	
		YOUNG et al (1999) "A new pathway for the secretion of virulence factors by bacteria: the flagellar export apparatus functions as a protein secretion system." PNAS 96:6456-6461	
		ZHU et al. (1993) "Systemic gene expression intravenous DNA delivery into adult mice." Science 261:209-211	
		ACHARYA et al. (1987) "Prevention of typhoid fever in nepal with the vi capsular polysaccharide of <i>Salmonella typhi</i> ," NEJM, 317:1101-1104	
		AHMER et al. (1999) " <i>Salmonella</i> SirA is a global regulator of genes mediating enteropathogenesis," Mol. Microbiol. 31(3):971-982.	
		ALTARE et al. (1998) "Inherited interleukin 12 deficiency in a child with Bacille Calmette-Guerin and <i>Salmonella enteritidis</i> disseminated infection," J. Clin. Invest. 102:2035-2040	
		ANGELAKOPOULOS and HOHMANN (2000) "Pilot study of <i>phoP/phoQ</i> -deleted <i>Salmonella enterica</i> serovar Typhimurium expressing <i>Helicobacter pylori</i> urease in adult volunteers," Infect. Immun., 68:2134-2141.	
		ARANDA et al. (1992) " <i>Salmonella typhimurium</i> activates virulence gene transcription within acidified macrophage phagosomes," PNAS, 89:10079-10083	
		ARRICAU et al. (1998) "The RcsB-RcsC regulatory system of <i>Salmonella typhi</i> differentially modulates the expression of invasion proteins, flagellin and Vi antigen in response to osmolarity," Mol. Microbiol. 29:835-850.	
		ASCON, et al. (1998) "Oral immunization with a <i>Salmonella typhimurium</i> vaccine vector expressing recombinant enterotoxigenic <i>Escherichia coli</i> K99 fimbriae elicits elevated antibody titers for protective immunity," Infect. Immun. 66:5470-5476	
		ATTRIDGE (1991) "Oral immunization with <i>Salmonella typhi</i> Ty21a-based clones expressing <i>Vibrio cholerae</i> O-antigen: serum bactericidal antibody responses in man in relation to pre-immunization antibody levels," Vaccine, 9:877-882	

Examiner Signature:		Date Considered	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SHEET 25 OF 51

**INFORMATION DISCLOSURE
STATEMENT LIST**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		BAO and CLEMENTS (1991) "Prior immunologic experience potentiates the subsequent antibody response when <i>Salmonella</i> strains are used as vaccine carriers," Infect. Immun. 59:3841-3845	
		BARRY et al. (1996) "Expression and Immunogenicity of Pertussis Toxin S1 subunit-tetanus toxin fragment C fusion in <i>Salmonella typhi</i> vaccine strain CVD 908," Infect. Immun. 64:7472-4781.	
		BASSO et al. (2002) "Characterization of a novel intracellularly activated gene from <i>Salmonella enterica</i> serovar typhi," Infect. Immun. 70:5404-5411	
		BENJAMIN et al. (1991) "A <i>hemA</i> mutation renders <i>Salmonella typhimurium</i> avirulent in mice, yet capable of eliciting protection against intravenous infection with <i>S. typhimurium</i> ," Microb. Pathog. 11:289-295.	
		BEUZON et al. (1999) "pH-dependant secretion of SseB, a product of the SPI-2 type III secretion system of <i>Salmonella typhimurium</i> ," Mol. Microbiol. 33:806-816	
		BEUZON et al. (2000) " <i>Salmonella</i> maintains the integrity of its intracellular vaciole through the action of SifA," EMBO J., 19:3235-3249	
		BLACK, et al. (1983) "Immunogenicity of Ty21a Attenuated <i>Salmonella typhi</i> given with sodium bicarbonate or in enteric-coated capsules," Develop. Biol. Stand., 53:9-14.	
		BOST and CLEMENTS (1995) "In vivo induction of interleukin-12 mRNA epxression after oral immunization with <i>Salmonella dublin</i> or the B subunit of <i>Escherichia coli</i> heat-labile enterotoxin," Infect. Immun. 63:1076-1083	
		BRENNAN et al. (1994) "Differences in the immune responses of mice and sheeo ti an aromatic-dependent mutant of <i>Salmonella typhimurium</i> ," J. Med. Microbiol. 41:20-28	
		BROWN and HORMAECHE (1989) "The antibody response to salmonellae in mice and humans studied y immunoblots and ELISA," Microb. Pathog. 6:445-454	
		BROWN et al. (1987) "An attenuated <i>aroA</i> <i>Salmonella typhimurium</i> vaccine elicits humoral and cellular immunity to cloned β -galactosidase in mice," J. Infect. Dis. 155:86-92	
		BROWNE et al. (2002) "Genetic requirements for <i>Salmonella</i> -induced cytopathology in human monocyte-derived macrophages," Infect. Immun. 70:7126-7135	
		BUCHMEIER and LIBBY (1997) "Dynamics of growth and death within a <i>Salmonella typhimurium</i> population during infection of macrophages," Can. J. Microbiol. 43:29-34	

Examiner Signature:		Date Considered	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

**INFORMATION DISCLOSURE
STATEMENT LIST**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		BUMANN et al. (2000) "Recombinant live <i>Salmonella</i> spp. for human vaccination against heterologous pathogens," FEMS Immunol. Med. Microbiol. 27:357-364	
		BUMANN et al. (2002) "Safety and immunogenicity of live recombinant <i>Salmonella enterica</i> serovar typhi Ty21a expressing urease A and B from <i>Helicobacter pylori</i> in human volunteers," Vaccine, 20:845-852.	
		BUTLER, et al. (1991) "Pattern of morbidity and mortality in typhoid fever dependent on age and gender: review of 552 hospitalized patients with diarrhea," Rev. Infect. Dis. 13:85-90.	
		CAMERON and FULS (1976) "Immunizaion of mice and calves agaist <i>Salmonella dublin</i> with attenuated live and inactivated vaccines," J. Vet. Res. 43:31-38	
		CANCELLIERI and FARA (1985) "Demonstration of specific IgA in human feces after immunization with live Ty21a <i>Salmonella typhi</i> vaccine," J. Infect. Dis. 151:482-484	
		CARO, et al. (1999) "Physiological changes of <i>Salmonella typhimurium</i> cells under osmotic and starvation conditions by image analysis," FEMS Microbiol. Lett. 179:265-273	
		CARRIER, et al. (1992) "Expression of Human IL-1 β in <i>Salmonella typhimurium</i> , a model system for the delivery of recombinant therapeutic proteins in vivo," J. Immunol. 148:176-181	
		CARTER and COLLINS (1974) "Growth of typhoid and paratyphoid Bacilli in travenously infected mice," Infect. Immun. 10:816-822	
		CASADEVALL (1998) "Antibody-mediated protection against intracellular pathogens," Trends in Microbiol. 6:102-107	
		CHABALGOITY et al. (1995) "Influence of preimmunization with tetanus toxoid on immune responses to tetanus toxin fragment c-guest antigen fusions in <i>Salmonella</i> vaccine carrier," Infect. Immun. 63:2564-2569	
		CHABALGOITY et al. (1997) "Expression and immunogenicity of an <i>Echinococcus granulosus</i> fatty acid-binding protein in live attenuated <i>Salmonella</i> vaccine strains," Infect. Immun. 65:2402-2412	
		CHARLES et al. (1990) "Isolation, characterization and nucleotide sequences of the <i>aroC</i> genes encoding chorismate synthase from <i>Salmonella typhi</i> and <i>Escherichia coli</i> ," J. Gen. Microbiol. 136:353-358	

Examiner Signature:		Date Considered	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

Application Number.	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		CHATFIELD, et al. (1992) "Use of the <i>nirB</i> promoter to direct the stable expression of heterologous antigens in <i>Salmonella</i> oral vaccine strains: development of a single-dose oral tetanus vaccine," Biotechnol. 10:888-892	
		CHATFIELD, et al. (1992) "Evaluation of <i>Salmonella typhimurium</i> strains harbouring defined mutations in <i>htrA</i> and <i>aroA</i> in the murine salmonellosis model," Microbial Pathog. 12:145-151	
		CHATFIELD, et al. (1994) "Progress in Development of Multivalent Oral Vaccines Based on Live Attenuated <i>Salmonella</i> " in <i>Modern Vaccinology</i> E. Kurstak, ed., Plenum Medical, New York, NY. 55-85	
		CHEN and SCHIFFERLI (2001) "Enhanced immune responses to viral epitopes by combining macrophage-inducible expression with multimeric display on a <i>Salmonella</i> vector," Vaccine, 19:3009-3018	
		CHEN, et al (1996) "Salmonella spp. are cytotoxic for cultured macrophages," Mol. Microbiol. 21:1101-1115	
		CHUTTANI, et al. (1973) "Ineffectiveness of an oral killed typhoid vaccine in a field trial," Bull. Org. Mond. Sante, 48:756-757	
		CHUTTANI, et al. (1977) "Controlled field trial of a high-dose oral killed typhoid vaccine in India," WHO 55:643-644.	
		CIACCI-WOOLWINE et al. (1997) "Salmonellae activate tumor necrosis factor alpha production in a human promonocytic cell line via a released polypeptide," Infect. Immun. 65:4624-4633	
		CIESLAK et al. (1993) "Expression of a recombinant <i>Entamoeba histolytica</i> antigen in a <i>Salmonella typhimurium</i> vaccine strain," Vaccine 11:773-776	
		CLAIRMONT et al. (2000) "Biodistribution and genetic stability of the novel antitumor agent VPN20009, a genetically modified strain of <i>Salmonella typhimurium</i> " J. Infect. Dis. 181:1996-2002	
		CLARK, et al. (1996) "Invasion of murine intestinal M cells by <i>Salmonella typhimurium inv</i> mutants severely deficient for invasion of cultured cells," Infect. Immun. 64:4363-4368	
		CLARK, et al. (1998) "Inoculum composition and <i>Salmonella</i> pathogenicity island 1 regulate M-cell invasion and epithelial destruction by <i>Salmonella typhimurium</i> ," Infect. Immun. 66:724-731	
		CLEMENTS and EL-MORSHIDY (1984) "Construction of a potential live oral bivalent vaccine for typhoid fever and cholera- <i>Escherichia coli</i> -Related diarrheas," Infect. Immun. 46:564-569	

Examiner Signature:	Date Considered
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SHEET 28 OF 51

**INFORMATION DISCLOSURE
STATEMENT LIST**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		CLEMENTS et al. (1986) "Oral immunization of mice with attenuated <i>Salmonella enteritidis</i> containing a recombinant plasmid which codes for production of the B subunit of heat-labile <i>Escherichia coli</i> enterotoxin," Infect. Immun. 53:685-692	
		COBELENS, et al. (2000) "Typhoid fever in groups of travelers: Opportunity for studying vaccine efficacy," J. Travel Med. 7:19-24	
		COLLINS and CARTER (1972) "Comparative immunogenicity of heat-killed and living oral <i>Salmonella</i> vaccines," Infect. Immun. 6:451-458	
		COLLINS (1972) "Salmonellosis in orally infected specific pathogen-free C57Bl mice," Infect. Immun. 5:191-198	
		COOPER et al. (1992) "Vaccination of chickens with chicken-derived <i>Salmonella enteritidis</i> phage type 4 <i>aroA</i> live oral salmonella vaccines," Vaccine 10:247-254	
		CORBEL (1996) "Reasons for instability of bacterial vaccines," Dev. Biol. Stand. 87:113-124.	
		COULSON et al. (1994) " <i>Bacillus anthracis</i> protective antigen, expressed in <i>Salmonella typhimurium</i> SL 3261, affords protection against anthrax spore challenge," Vaccine, 12:1395-1401	
		COULSON et al. (1994) "Effect of different plasmids on colonization of mouse tissues by the aromatic amino acid dependent <i>Salmonella typhimurium</i> , SL 3261," Microbial Pathog. 16:305-311	
		COYNAULT and NORAL (1999) "Comparison of the abilities of <i>Salmonella typhimurium rpoS</i> , <i>aroA</i> and <i>rpoS aroA</i> strains to elicit humor immune responses in BALB/c mice to cause lethal infection in athymic BALB/c mice," Microbial Pathog. 26:299-305	
		COYNAULT et al. (1996) "Virulence and vaccine potential of <i>Salmonella typhimurium</i> mutants deficient in the expression of the RpoS σ^S regulon," Mol. Microbiol. 22:149-160	
		CRYZ et al. (1989) "Construction and characterization of a Vi-positive variant of the <i>Salmonella typhi</i> live oral vaccine strain Ty21a," Infect. Immun. 57:3863-3868	
		CRYZ et al. (1995) "Safety and immunogenicity of a live oral bivalent typhoid fever (<i>Salmonella typhi</i> Ty21a)-cholera (<i>Vibrio cholerae</i> CVD 103-HgR) vaccine in healthy adults," Infect. Immun. 63:1336-1339	
		CURTISS and KELLY (1987) " <i>Salmonella typhimurium</i> deletion mutants lacking adenylate cyclase and cyclic AMP receptor protein are avirulent and immunogenic," Infect. Immun. 55:3035-3043	

Examiner Signature:	Date Considered
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

**INFORMATION DISCLOSURE
STATEMENT LIST**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		CURTISS et al. (1989) "Recombinant avirulent <i>Salmonella</i> vaccine strains with stable maintenance and high level expression of cloned genes in vivo," Immunol. Invest. 18:583-596	
		D'AMELIO et al. (1988) "Comparative analysis of immunological responses to oral (Ty21a) and parenteral (TAB) typhoid vaccines," Infect. Immun.. 56:2731-2735	
		DE ALMEIDA (1999) "Antibody responses against flagellin in mice orally immunized with attenuated <i>Salmonella</i> vaccine strains," Arch. Microbiol. 172:102-108	
		DHAM and THOMPSON (1982) "Studies of cellular and humoral immunity in typhoid fever and TAB vaccinated subjects," Clin. Exp. Immunol. 48:389-395.	
		DILTS, et al. (2000) "Phase I clinical trials of <i>aroA aroD</i> and <i>aroA aroD htrA</i> attenuated <i>S. typhi</i> vaccines; effect of formulation on safety and immunogenicity," Vaccine, 18:1473-1484	
		DIMA (1981) "Isolation and characterization of two <i>Salmonella typhosa</i> mutants for possible use as a live oral attenuated vaccinal strains," Arch. Roum. Path. Exp. Microbiol. 40:33-40	
		DEPETRILLO (2000) "Safety and immunogenicity of <i>PhoP/PhoQ</i> -deleted <i>Salmonella typhi</i> expressing <i>Helicobacter pylori</i> urease in adult volunteers," Vaccine 18:449-459.	
		DJAVANI et al. (2001) "Mucosal immunization with <i>Salmonella typhimurium</i> expressing Lassa virus nucleocapsid protein cross-protects mice from lethal challenge with lymphocytic choriomeningitis virus," J. Hum. Virol. 4:103-108	
		DORMAN et al. (1989) "Characterization of porin and <i>ompR</i> mutants of a virulent strain of <i>Salmonella typhimurium</i> : <i>ompR</i> mutants are attenuated in vivo," Infect. Immun. 57:2136-2140	
		DORNER (1995) "An overview of vaccine vectors," Dev. Biol. Stand. 84:23-32	
		DOUCE, et al. (1991) "Invasion of HEp-2 cells by strains of <i>Salmonella typhimurium</i> different virulence in relation to gastroenteritis," J. Med. Microbiol. 35:349-357	
		DOUGAN, et al. (1988) "Construction and characterization of vaccine strains of <i>Salmonella</i> harboring mutations in two different <i>aro</i> genes," J. Infect. Dis. 158:1329-1335	
		DRAGUNSKY et al. (1990) "In vitro characterization of <i>Salmonella typhi</i> mutant strains for live oral vaccines," Vaccine 8:263-268	
		DRAGUNSKI et al. (1989) "Salmonella typhi vaccine strain in vitro; low infectivity in human cell line U937," J. Biol. Stand. 17:353-360.	

Examiner Signature:	Date Considered
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		DUNSTAN et al. (1999) "Use of in vivo-regulated promoters to deliver antigens from attenuated <i>Salmonella enterica</i> var. Typhimurium," Infect. Immun. 67:5133-5141	
		DUPONT et al. (1971) "Studies of immunity in typhoid fever," Bull. Org. Mond. Sante. 44:667-672	
		EDWARDS and STOCKER (1988) "Construction of Δ aroA his Δ pur strains of <i>Salmonella typhi</i> ," J. Bacteriol. 170:3991-3995	
		EICHELBERG and GALAN (1999) "Differential regulation of <i>Salmonella typhimurium</i> type III secreted proteins by pathogenicity island 1 (SPI-1)-encoded transcriptional activators InvF and HilA," Infect. Immun. 67:4099-4105	
		EMMERTH, et al. (1999) "Genomic subtraction identifies <i>Salmonella typhimurium</i> prophages, F-related plasmid sequences, and a novel fimbrial operon, stf, which are absent in <i>Salmonella typhi</i> ," J. Bacteriol. 181:5652-5661	
		ENGELS, et al. (1998) "Typhoid fever vaccines: a meta-analysis of studies on efficacy and toxicity," BMJ, 316:110-113	
		EVEREST, et al. (1999) "Evaluation of <i>Salmonella typhimurium</i> Mutants in a model of experimental gastroenteritis," Infect. Immun. 67:2815-2821.	
		FALLON, et al. (1991) "Mouse hepatitis virus strain UAB infection enhances resistance to <i>Salmonella typhimurium</i> in mice by inducing suppression of bacterial growth," Infect. Immun. 59:852-856.	
		FERRICIO (1989) "Comparative efficacy of two, three or four doses of TY21a live oral vaccine in enteric coated capsules: a field trial in an endemic area," J. Infect. Dis. 159:766-769	
		FINLAY and FALKOW (1997) "Common themes in microbial pathogenicity revisited," Microbiol. Mol. Biol. Rev. 61:136-169.	
		FORMAL et al. (1981) "Construction of a potential bivalent vaccine strain: introduction of <i>Shigella sonnei</i> form I antigen genes into the <i>galE</i> <i>Salmonella typhi</i> Ty21a typhoid vaccine strain," Infect. Immun. 34:746-750	
		FORREST and LaBrooy (1993) "Effect of parenteral immunization on intestinal immune response to <i>Salmonella typhi</i> Ty21a as measured using peripheral blood lymphocytes," Vaccine, 11:136-139	

Examiner Signature:	Date Considered
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SHEET 31 OF 51

**INFORMATION DISCLOSURE
STATEMENT LIST**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		FU and GALAN (1998) "The <i>Salmonella typhimurium</i> tyrosine phosphatase SptP is translocated into host cells and disrupts the actin cytoskeleton," Mol. Microbiol. 27:359-368	
		GAHRING, et al. (1990) "Invasion and replication of <i>Salmonella typhimurium</i> in animal cells," Infect. Immun. 58:443-448	
		GALAN and COLIMER (1999) "Type III secretion machines: bacterial devices for protein delivery into host cells," Science, 284:1322-1328	
		GALAN and ZHOU (2000) Striking a balance: modulation of the actin cytoskeleton by <i>Salmonella</i> . PNAS, 97:8754-8761	
		GALAN, et al (1990) "Cloning and characterization of the <i>asd</i> gene of <i>Salmonella typhimurium</i> : use in a stable maintenance of recombinant plasmids in <i>Salmonella</i> vaccine strains," Gene, 94:29-35	
		GALAN and LEVINE (2001) "Can a 'flawless' love vector strain be engineered?" Trends in Microbiol. 9:372-376	
		GALAN (1996) "Molecular genetic bases of <i>Salmonella</i> entry into host cells," Mol. Microbiol. 20:263-271	
		GALEN et al. (1999) "Optimization of plasmid maintenance in attenuated live vector vaccine strain <i>Salmonella typhi</i> CVD 908- <i>htrA</i> " Infect. Immun. 67:6424-6433	
		GARCIA-DEL PORTILLO, et al. (1993) " <i>Salmonella</i> induces the formation of filament structures containing lysosomal membrane glycoproteins in epithelial cells," PNAS, 90:10544-10548	
		GARMORY et al. (2002) " <i>Salmonella</i> vaccines for use in humans: present and future perspectives," FEMS Microbiol. Rev. 26:339-353	
		GAUTIER et al. (1998) "Mouse susceptibility to infection by the <i>Salmonella abortusovus</i> vaccine strain Rv6 is controlled by the <i>Ity/Nramp 1</i> gene and influences the antibody response but not the complement response," Microbial Pathog. 24:47-55	
		GENTSCHEV et al. (2000) "Delivery of protein antigens and DNA by virulence attenuated strains of <i>Salmonella typhimurium</i> and <i>Listeria monocytogenes</i> ," J. Bacteriol. 83:19-26	
		GERMANIER and FURER (1975) "Isolation and characterization of <i>Gal E</i> mutant Ty21a of <i>Salmonella typhi</i> : a candidate strain for a live oral typhoid vaccine," J. Infect. Dis. 131:553-558	
		GERMANIER and LEVINE (1986) "The live typhoid vaccine Ty21a: recent field trial results," Bacterial Vaccines and Local Immunity:19-22	

Examiner Signature:	Date Considered
---------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		GEWIRTZ et al (1999) "Orchestration of neutrophil movement by intestinal epithelial cells in response to <i>Salmonella typhimurium</i> can be uncoupled from bacterial internalization," Infect. Immun. 67:608-617	
		GILMAN (1977) "Evaluation of UDP-glucose-4-epimeraseless mutant of <i>Salmonella typhi</i> as a live oral vaccine," J. Infect. Dis. 130:717-723	
		GIRON et al. (1995) "Simultaneous expression of CFA/I and CS3 colonization factor antigens of enterotoxigenic <i>Escherichia coli</i> by Δ aroC, Δ aroD <i>Salmonella typhi</i> vaccine strain CVD 908," Vaccine, 13:939-946	
		GONZALES, et al. (1994) " <i>Salmonella typhi</i> vaccine strain CVD 908 expressing the circumsporozoite protein of <i>Plasmodium falciparum</i> : Strain construction and safety and immunogenicity in humans," J. Infect. Dis. 169:927-931	
		GONZALES et al. (1998) "Immunogenicity of a <i>Salmonella typhi</i> CVD 908 candidate vaccine strain expressing the major surface protein gp63 of <i>Leishmania mexicana mexicana</i> ," Vaccine 16:1043-1052	
		GROSSMAN et al. (1995) "Flagellar serotypes of <i>Salmonella typhi</i> in Indonesia: Relationships among motility, invasiveness, and clinical illness" J. Infect. Dis. 171:212-216	
		GUARD-PETTER, et al. (1995) "Characterization of lipopolysaccharide heterogeneity in <i>Salmonella enteritidis</i> by an improved gel electrophoresis method," Appl. Environ. Microbiol., 61:2845-2851	
		GUERRANT and KOSEK (2001) "Polysaccharide conjugate typhoid vaccine," NEJM, 344:1322-1323	
		GUILLOBEL et al. (2000) "Adjuvant activity of a nontoxic mutant <i>Escherichia coli</i> heat-labile enterotoxin on systemic and mucosal immune responses elicited against a heterologous antigen carried by a live <i>Salmonella enterica</i> serovar typhimurium vaccine strain," 68:4349-4353.	
		GUNN et al. (1995) "Characterization of the <i>Salmonella typhimurium</i> pagC/pagD Chromosomal region," J. Bacteriol. 177:5040-5047	
		GUO et al. (1997) "Regulation of lipid modifications by <i>Salmonella typhimurium</i> virulence genes <i>phoP-phoQ</i> ," Science, 276:250-253	
		HACKET (1993) "Use of <i>Salmonella</i> for heterologous gene expression and vaccine delivery systems," Curr. Opin. Biotechnol. 4:611-615.	

Examiner Signature:	Date Considered
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		HALL and TAYLOR (1970) "Salmonella Dublin: The relation between a living calf vaccine strain and those isolated from human and other sources," Vet. Rec. 86:534-536.	
		HARRISON et al. (1997) "Correlates of protection induced by live Aro ⁻ <i>Salmonella typhimurium</i> vaccines in the murine typhoid model," Immunol. 90:618-625	
		HERRINGTON et al. (1990) "Studies in volunteers to evaluate candidate <i>Shigella</i> vaccines: further experience with a bivalent <i>Salmonella typhi</i> - <i>Shigella sonnei</i> vaccine and protection conferred by previous <i>Shigella sonnei</i> disease," Vaccine, 8:353-357	
		HESS et al. (1996) " <i>Salmonella typhimurium</i> aroA ⁻ infection in gene-targeted immunodeficient mice; major role of CD4 ⁺ TCR- $\alpha\beta$ cells in IFN- γ in bacterial clearance independent of intracellular location," J. Immunol. 156:3321-3326	
		HINDLE et al. (2002) "Characterization of <i>Salmonella enterica</i> derivatives harboring defined aroC and <i>Salmonella</i> pathogenicity island 2 type III secretion system (<i>ssaV</i>) mutations by immunization of healthy volunteers," Infect. Immun. 70:3457-3467	
		HIROSE et al. (1997) "Survival of Vi-capsulated and Vi-deleted <i>Salmonella typhi</i> strains in cultured macrophage expressing different levels of CD14 antigen," FEMS Microbiol. Lett. 147:259-265	
		HOHMANN and OLETTA (1996) " <i>phoP/phoQ</i> - deleted <i>Salmonella typhi</i> (Ty800) is safe and immunogenic single-dose fever vaccine in volunteers," J. Infect. Dis. 173:1408-1414	
		HOISTH and STOCKER (1981) "Aromatic-dependent <i>Salmonella typhimurium</i> are non-virulent and effective as live vaccines," Nature, 291:238-239	
		HOLDEN (2002) "Trafficking of the <i>Salmonella</i> vacuole in macrophages," Traffic, 3:1-11	
		HOLMSTROM, et al. (1999) "Physiological states of individual <i>Salmonella typhimurium</i> cells monitored by in situ reverse transcription PCR," J. Bacteriol. 181:1733-1738	
		HONE et al. (1988) "A <i>galE</i> via (Vi antigen-negative) mutant <i>Salmonella typhi</i> Ty2 retains virulence in humans," Infect. Immun. 56:1326-1333.	
		HONE et al (1991) "Construction of genetically defined double aro mutants of <i>Salmonella typhi</i> ," Vaccine, 9:810-816	
		HONE et al. (1992) "Evaluation in volunteers of candidate live oral attenuated <i>Salmonella typhi</i> vector vaccine," J. Clin. Invest. 90:412-420	

Examiner Signature:	Date Considered
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SHEET 34 OF 51

**INFORMATION DISCLOSURE
STATEMENT LIST**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		HONE, et al. (1994) "Adaptive acid tolerance response by <i>Salmonella typhi</i> and candidate live oral typhoid vaccine strains," Vaccine, 12:895-898	
		HOPKINS, et al. (1995) "A recombinant <i>Salmonella typhimurium</i> vaccine induces local immunity by four different routes of immunization," Infect. Immun. 63:3279-3286	
		HORMAECHE (1979) "Natural resistance to <i>Salmonella typhimurium</i> in different inbred mouse strains," Immunol. 37:311-318	
		HORNICK (1970) "Typhoid fever: pathogenesis and immunologic control," NEJM, 283: 739-742.	
		HOUSE, et al. (2001) "Typhoid fever: pathogenesis and disease," Curr. Opin. Infect. Dis. 14:573-578.	
		HUMPHREYS, et al. (1999) The alternative sigma factor, σ^E is critically important for the virulence of <i>Salmonella typhimurium</i> ," Infect. Immun. 67:1560-1568	
		ISHIBASHI and ARAI (1995) " <i>Salmonella typhi</i> does not inhibit phagosome-lysosome fusion in human monocyte derived macrophages," FEMS Immunol. Med. Microbiol. 12:55-62	
		IVANOFF, et al. "Vaccination against typhoid fever: present status," WHO Bull. DMS, 72:957-971	
		JEPSON et al. (1996) "Evidence for a rapid, direct effect on epithelial monolayer integrity and transepithelial transport in response to <i>Salmonella</i> invasion," Eur. J. Physiol. 432:225-233.	
		JOHNSTON et al. (1996) "Transcriptional activation of <i>Salmonella typhimurium</i> invasion genes by a member of the phosphorylated response-regulator superfamily," Mol. Microbiol. 22:715-727.	
		JONES et al. (1981) "The invasion of HeLa cells by <i>Salmonella typhimurium</i> : Reversible and irreversible bacterial attachment and the role of bacterial motility," J. Gen. Microbiol. 127:351-360.	
		KANTELE, et al. (1991) "Comparison of the human immune response to live oral, killed oral or killed parenteral <i>Salmonella typhi</i> Ty21A vaccines," Microbial Pathog. 10:117-126	
		KANTELE et al. (1998) "Differences in immune responses induced by oral and rectal immunizations with <i>Salmonella typhi</i> TY21a: Evidence for compartmentalization within the common mucosal immune system in humans," Infect. Immun. 66:5630-5635	

Examiner Signature:		Date Considered	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		KAREM, et al. (1995) "Differential induction of carrier antigen-specific immunity by <i>Salmonella typhimurium</i> live-vaccine strains after single mucosal or intravenous immunization of Balb/c mice," Infect. Immun. 63:4557-4563	
		KAREM, et al. (1997) "Protective immunity against herpes simplex (HSV) type 1 following oral administration of recombinant <i>Salmonella typhimurium</i> vaccine strains expressing HSV antigens," J. Gen. Virol. 78:427-434.	
		KAUFMAN and HESS (1999) "Impact of intracellular location of and antigen display by intracellular bacteria: implications for vaccine development," Immunol. Lett. 65:81-84.	
		KAWAKAMI, et al. (1969) "Experimental Salmonellosis immunizing effect of live vaccine prepared from various mutants of <i>Salmonella</i> having different cell wall polysaccharides," Japan. J. Microbiol. 13:315-324	
		KEDDY, et al. (1998) "Efficacy of Vi polysaccharide vaccine against strains of <i>Salmonella typhi</i> : reply" Vaccine, 16:871-872	
		KEHRES, et al. (2000) "The NRAMP proteins of <i>Salmonella typhimurium</i> and <i>Escherichia coli</i> are selective manganese transporters involved in the response to reactive oxygen," Mol. Microbiol. 36:1085-1100.	
		KEITEL, et al. (1994) "Clinical and serological responses following primary and booster immunizations with <i>Salmonella typhi</i> Vi capsular polysaccharide vaccines," 12:195-199	
		KELLY, et al. (1992) "Characterization and protective properties of attenuated mutants of <i>Salmonella choleraesuis</i> ," Infect. Immun. 60:4881-4890	
		KEREN, et al. (1978) "The role of peyer's patches in the local immune response of rabbit ileum to live bacteria," J. Immunol. 120:1892-1896	
		KHAN, et al. (1998) " <i>Salmonella typhi</i> rpoS mutant is less cytotoxic than the parent strain but survives inside resting THP-1 macrophages," FEMS Microbiol. Lett. 161:201-208	
		KHAN et al. (1998) "A lethal role for lipid A in <i>Salmonella</i> infections," Mol. Microbiol. 29:571-579	
		KHAN et al. (2001) "Early responses to <i>Salmonella typhimurium</i> infection in mice occur at focal lesions in infected organs," Microbial Pathog. 30:29-38	

Examiner Signature:		Date Considered	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SHEET 36 OF 51

**INFORMATION DISCLOSURE
STATEMENT LIST**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		KHAN et al. (2003) "Salmonella typhi and S. typhimurium derivatives harbouring deletions in aromatic biosynthesis and Salmonella pathogenicity island-2 (SPI-2) genes as vaccines and vectors," Vaccine, 21:538-548	
		KHAN, et al. (2007) "Ability of SPI2 mutant of S. typhi to effectively induce antibody responses to the mucosal antigen enterotoxigenic E. coli heat labile toxin B subunit after oral delivery to humans," Vaccine, 25:4175-4182	
		KINGSLEY and BAUMLER (2000) "Host adaptation and the emergency of infectious disease: the Salmonella paradigm," 1006-1014	
		KIRKPATRICK, et al. (2005) "Comparison of the antibodies in lymphocyte supernatant and antibody-secreting cells assays for measuring intestinal mucosal immune response to a novel oral typhoid vaccine (M01ZH09)" Clin. Diagnostic Lab. Immunol. 12:1127-1129	
		KIRKPATRICK et al. (2005) "The novel oral typhoid vaccine M01ZH09 is well tolerated and highly immunogenic in 2 vaccine presentations," J. Infect. Dis. 192:360-366	
		KIRKPATRICK, et al. (2006) "Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers," Vaccine, 24:116-123	
		KLUGMAN, et al. (1987) "Protease activity of Vi capsular polysaccharide vaccine against typhoid fever," Lancet, 1165-1169	
		KOHBATA, et al. (1986) "Cytopathogenic effect of Salmonella typhi GIFU 10007 on M cells of murine ileal peyer's patches in ligated ileal loops: an ultrastructural study," Microbiol. Immunol. 30:1225-1237	
		KOHLER et al., (2000) "Effect of preexisting immunity to Salmonella on the immune response to recombinant Salmonella enterica serovar typhimurium expressing a Porphyromonas gingivalis hemagglutinin," Infect. Immun. 68:3116-3120	
		KOLLARITSCH et al. (1996) "Randomized double-blind placebo-controlled trial to evaluate the safety and immunogenicity of combined Salmonella typhi Ty21a and Vibrio cholerae CVD 103-HgR live oral vaccines," Infect. Immun. 64:1454-1457	
		KOLLARITSCH et al. (1997) "Safety and immunogenicity of live oral Cholera and Typhoid vaccines administered alone or in combination with antimalarial drugs, oral polio vaccines, or yellow fever vaccine," J. Infect. Dis. 871-875	

Examiner Signature:

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

**INFORMATION DISCLOSURE
STATEMENT LIST**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		KOLLARITSCH, et al. (2000) "Local and systemic immune responses to combined <i>Vibrio cholerae</i> CVD103-HgR and <i>Salmonella typhi</i> Ty21a live oral vaccines after primary immunization and reimmunization," Vaccine 18:3031-3039.	
		KOTLOFF, et al. (1996) "Safety, immunogenicity, and transmissibility in humans in CVD 1203 a live oral <i>Shigella flexneri</i> 2a vaccine candidate attenuated by deletions in <i>aroA</i> and <i>virG</i> ," Infect. Immun. 64:4542-4548	
		KRAMER and VOTE (2000) "Granulocyte selected live <i>Salmonella enteritidis</i> vaccine is species specific," Vaccine, 18:2239-2243	
		LALMANACH and LANTIER (1999) "Host cytokine response and resistance to <i>Salmonella</i> infection," Microbes Infect. 1:719-726	
		LEBACQ (2001) "Comparative tolerability and immunogenicity of Typherix TM or Typhium Vi TM in healthy adults," Drugs, 15 Suppl. 1:5-12	
		LECLERC, et al. (1998) "Environmental regulation of <i>Salmonella typhi</i> invasion-defective mutants," Infect. Immun. 66:682-691	
		LEE and SCHNEEWIND (1999) "Type III secretion machines and the pathogenesis of enteric infections caused by <i>Yersinia</i> and <i>Salmonella</i> spp." Immunol. Rev. 168:241-255	
		LEE et al. (2000) "Surface-displayed viral antigens on <i>Salmonella</i> carrier vaccine," Nature Biotechnol. 18:645-648	
		LEE et al. (2000) "OmpR regulates the two-component system SsrA-SsrB in <i>Salmonella</i> pathogenicity island 2," J. Bacteriol. 182:771-781	
		LEHOUX et al. (1999) "Defined oligonucleotide tag pools and PCR screening in signature-tagged mutagenesis of essential genes from bacteria," BioTechniques 26:473-480	
		LEUNG and FINLAY (1991) "Intracellular replication is essential for the virulence of <i>Salmonella typhimurium</i> ," PNAS 88:11470-11474	
		LEVINE and SZTEIN (1996) "Human mucosal vaccines for <i>Salmonella typhi</i> infections," in <i>Mucosal Vaccines</i> , Kiyono, et al., eds. Academic Press, San Diego.	
		LEVINE, et al. (1985) "The efficacy of attenuated <i>Salmonella typhi</i> oral vaccine strain Ty21a evaluated in controlled field trials," Dev. Vaccines and Drugs against diarrhea, 11 th Nobel Conf. Stockholm, pp.90-101	

Examiner Signature:	Date Considered
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

**INFORMATION DISCLOSURE
STATEMENT LIST**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		LEVINE et al. (1987) "Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of <i>Salmonella typhi</i> , 541Ty and 543Ty, as live oral vaccines in human," J. Clin. Invest. 79:888-902	
		LEVINE (1987) "Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation." Lancet, 1049-1052	
		LEVINE et al. (1989) "Progress in vaccines against typhoid fever," Rev. Infect. Dis. 11:S552-S567	
		LEVINE, et al. (1990) "Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial," Lancet, 336:891-894	
		LEVINE et al. (1997) "Attenuated <i>Salmonella typhi</i> and <i>Shigella</i> as live oral vaccines and as live vectors," Behring Inst. Mitt. 98:120-123	
		LEVINE, (1994) "Typhoid Fever Vaccines," in <i>Vaccines</i> , Plotkin and Mortimer, eds., W.B. Saunders Company, Philadelphia, 597-633	
		LEVINE, et al. (1999) "Duration of efficacy of Ty21a, attenuated <i>Salmonella typhi</i> live oral vaccine," Vaccine, 17:S22-S27	
		LEVINE, et al. (1997) "Attenuated <i>Salmonella</i> as a live vector for expression of foreign antigens. Part iii. <i>Salmonella</i> expressing protozoal antigens," in <i>New Generation Vaccines 2nd ed.</i> , Levine, et al., eds. Marcel Dekker, New York. 351-361	
		LEVINE et al. (2001) "Host- <i>Salmonella</i> interaction: human trials," Microbes Infect. 3:1271-1279	
		LIANG-TAKASAKI, et al. (1982) "Phagocytosis of bacteria by macrophages: Changing the carbohydrate of lipopolysaccharide alters interaction with complement and macrophages," J. Immunol. 128:1229-1235	
		LIANG-TAKASAKI et al. (1983) "Complement activation by polysaccharide of lipopolysaccharide: an important virulence determinant of <i>Salmonellae</i> ," Infect. Immun. 41:563-569	
		LIANG-TAKASAKI, et al. (1983) " <i>Salmonellae</i> activate complement differentially via the alternative pathway depending on the structure of their lipopolysaccharide O-antigen," J. Immunol. 130:1867-1870	

Examiner Signature:		Date Considered	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		LIBBY et al. (1994) "A cytolysin encoded by <i>Salmonella</i> is required for survival within macrophages," PNAS, 91:489-493	
		LIU, (1988) "Intact motility as <i>Salmonella typhi</i> invasion-related factor," Infect. Immun. 56:1967-1973	
		LODGE, et al. (1995) "Biological and genetic characterization of TnphoA mutants of <i>Salmonella typhimurium</i> TML in the context of gastroenteritis," Infect. Immun. 63:762-769	
		LONDONO et al. (1995) "Immunization of mice using <i>Salmonella typhimurium</i> expressing human papillomavirus type 16 E7 epitopes inserted into hepatitis B virus core antigen," Vaccine, 14:545-552	
		LOW, et al. (1999) "Lipid A mutant <i>Salmonella</i> with suppressed virulence and TNF α induction retain tumor-targeting in vivo," Nature Biotechnol. 17:37-41	
		LUCAS, et al. (2000) "Unravelling the mysteries of virulence gene regulation in <i>Salmonella typhimurium</i> ," Mol. Microbiol. 36:1024-1033	
		LUNDBERG, et al. (1999) "Growth phase-regulated induction of <i>Salmonella</i> -induced macrophage apoptosis correlates with transient expression of SPI-1 genes," J. Bacteriol. 181:3433-3437.	
		MARSHALL, et al. (2000) "Use of the stationary phase inducible promoters, spv and dps, to drive heterologous antigen expression in <i>Salmonella</i> vaccine strains," Vaccine 18: 1298-1306	
		MASTROENI, et al. (1998) "Interleukin-12 Is Required for Control of the Growth of Attenuated Aromatic-Compound-Dependent <i>Salmonellae</i> in BALB/c Mice: Role of Gamma Interferon and Macrophage Activation," Infect. Immun. 66: 4767-4776	
		MASTROENI, et al. (1995) "Effect of Anti-Tumor Necrosis Factor Alpha Antibodies on Histopathology of Primary <i>Salmonella</i> Infections," Infect. Immun. 63: 3674-3682	
		MASTROENI, et al. (1992) "Role of T cells, TNF α and IFN γ in recall of immunity to oral challenge with virulent salmonellae in mice vaccinated with live attenuated aro- salmonella vaccines," Microbial Pathogen. 13: 477-491	

Examiner Signature:	Date Considered
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		MAZURKIEWICZ, et al. (2006) "Signature-tagged mutagenesis: barcoding mutants for genome-wide screens," Nat. Rev. Genet. 7: 929-939	
		MCFARLAND and STOCKER (1987) "Effect of different purine auxotrophic mutations on mouse-virulence of a Vi-positive strain of Salmonella dublin and of two strains of Salmonella typhimurium," Microbial Pathogen. 3: 129-141	
		MCSORLEY and JENKINS (2000) "Antibody Is Required for Protection against Virulent bu Not Attenuated Salmonella enterica Serovar Typhimurium," Infect. Immun. 68: 3344-3348	
		MEDINA and GUZMAN (2001) "Use of live bacterial vaccine vectors for antigen delivery: potential and limitations," Vaccine 19: 1573-1580	
		MIAO and MILLER (2000) "A conserved amino acid sequence directing intracellular type II secretion by Salmonella typhimurium," Proc. Natl. Acad. Sci. USA 97: 7539-7544	
		MILLS and FINLAY (1994) "Comparison of Salmonella typhi and Salmonella typhimurium invasion, intracellular growth and localization in cultured human epithelial cells," Microbial. Pathogen. 17: 409-423	
		MILLS, et al. (1998) "Trafficking of Porin-Deficient Salmonella typhimurium Mutants inside HeLa Cells: ompR and envZ Mutants Are Defective for the Formation of Salmonella-Induced Filaments," Infect. Immun. 66: 1806-1811	
		MINTZ, et al. (1983) "Effect of Lipopolysaccharide Mutations on the Pathogenesis of Experimental Salmonella Gastroenteritis," Infect. Immun. 40: 236-244	
		MITTRÜCKER and KAUFMANN (2000) "Immune response to infection with Salmonella typhimurium in mice," J. Leukoc. Biol. 67: 457-463	

Examiner Signature:	Date Considered
---------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		MITTRÜCKER, et al. (2000) "Cutting Edge: Role of B Lymphocytes in Protective Immunity Against Salmonella typhimurium Infection," J. Immunol 164: 1648-1652	
		MOLLENKOPF, et al. (2001) "Protective efficacy against tuberculosis of ESAT-6 secreted by a live Salmonella typhimurium vaccine carrier strain and expressed by naked DNA," Vaccine 19: 4028-4035	
		MOLLENKOPF, et al. (2001) "Intracellular Bacteria as Targets and Carriers for Vaccination," Biol. Chem. 382: 521-532	
		NARDELLI-HAEFLIGER, et al. (2001) "Nasal vaccination with attenuated Salmonella typhimurium strains expressing the Hepatitis B nucleocapsid: dose response analysis," Vaccine 19: 2854-2861	
		NARDELLI-HAEFLIGER, et al. (1996) "Oral and Rectal Immunization of Adult Female Volunteers with a Recombinant Attenuated Salmonella typhi Vaccine Strain," Infect. Immun. 64: 5219-5224	
		NAUCIEL and ESPINASSE-MAES (1992) "Role of Gamma Interferon and Tumor Necrosis Factor Alpha in Resistance to Salmonella typhimurium Infection," Infect. Immun. 60: 450-454	
		NAUCIEL (1990) "Role of CD4+ T Cells and T-Independent Mechanisms in Acquired Resistance to Salmonella typhimurium Infection," J. Immunol. 145: 1265-1269	
		NICKERSON and CURTISS III, et al. (1997) "Role of Sigma Factor RpoS," in Initial Stages of Salmonella typhimurium Infection," Infect. Immun. 65: 1814-1823	
		ORNELLAS, et al. (1970) "The Specificity and Importance of Humoral Antibody in the Protection of Mice against Intraperitoneal Challenge with Complement-Sensitive and Complement-Resistant Salmonella," J. Infect. Disease 121: 113-123	

Examiner Signature:	Date Considered
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		PAESOLD, et al. (2002) "Genes in the Salmonella pathogenicity island 2 and the Salmonella virulence plasmid are essential for Salmonella-induced apoptosis in intestinal epithelial cells," Cell. Microbiol. 4: 771-781	.
		PAGLIA, et al. (2000) "In vivo correction of genetic defects of monocyte/macrophages using attenuated Salmonella as oral vectors for targeted gene delivery," Gene Therapy 7: 1725-1730	
		PANG, et al. (1995) "Typhoid fever and other salmonellosis: a continuing challenge," Trends Microbiol. 3: 253-255	
		PICKARD, et al. (1994) "Characterization of Defined ompR Mutants of Salmonella typhi: ompR Is Involved in the Regulation of Vi Polysaccharide Expression," Infect. Immun. 62: 3984-3993	
		PICKETT, et al. (2000) "In Vivo Characterization of the Murine Intranasal Model for Assessing the Immunogenicity of Attenuated Salmonella enterica Serovar Typhi Strains as Live Mucosal Vaccines and as Live Vectors," Infect. Immun. 68: 205-213	
		PIE, et al. (1997) "Th1 Response in Salmonella typhimurium-Infected Mice with a High or Low Rate of Bacterial Clearance," Infect. Immun. 65: 4509-4514	
		PIER, et al. (1998) "Salmonella typhi uses CFTR to enter intestinal epithelial cells," Nature 393: 79-82	
		POIRER, et al. (1988) "Protective Immunity Evoked by Oral Administration of Attenuated araA Salmonella typhimurium Expressing Cloned Streptococcal M Protein," J. Exp. Med. 168: 25-32	
		PULKKINEN and MILLER (1991) "A Salmonella typhimurium Virulence Protein Is Similar to a Yersinia enterocolitica Invasion Protein and a Bacteriophage Lambda Outer Membrane Protein," J. Bacteriol. 173: 86-93	

Examiner Signature:

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		QIAN and PAN (2002) "Construction of a tetR-Integrated Salmonella enterica Serovar Typhi CVD908 Strain That Tightly Controls Expression of the Major Merozoite Surface Protein of Plasmodium falciparum for Applications in Human Vaccine Production," Infect. Immun. 70: 2029-2038	
		RAKEMAN, et al. (1999) "A HilA-Independent Pathway to Salmonella typhimurium Invasion Gene Transcription," J. Bacteriol. 181: 3096-3104	
		RICHTER-DAHLFORS, et al. (1997) "Murine Salmonellosis Studied by Confocal Microscopy: Salmonella typhimurium Resides Intracellularly Inside Macrophages and Exerts a Cytotoxic Effect on Phagocytes In Vivo," J. Exp. Med. 186: 569-580	
		ROBBE-SAULE, et al. (1995) "The live oral typhoid vaccine Ty21a is a rpoS mutant and is susceptible to various environmental stresses," FEMS Microbiol. Lett. 126: 171-176	
		ROBERTS, et al. (2000) "Comparison of Abilities of Salmonella enterica Serovar Typhimurium aroA aroD and aroA htrA Mutants To Act as Live Vectors," Infect. Immun. 68: 6041-6043	
		ROBERTS, et al. (1999) "Prior Immunity to Homologous and Heterologous Salmonella Serotypes Suppresses Local and Systemic Anti-Fragment C Antibody Responses and Protection from Tetanus Toxin in Mice Immunized with Salmonella Strains Expressing Fragment C," Infect. Immun. 67: 3810-3815	
		ROBERTS, et al. (1998) "Oral Vaccination against Tetanus: Comparison of the Immunogenicities of Salmonella Strains Expressing Fragment C from the nirB and htrA Promoters," Infect. Immun. 66: 3080-3087	

Examiner Signature:		Date Considered	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		ROLAND, et al. (1999) "Construction and Evaluation of a Δcya Δcrp Salmonella typhimurium Strain Expressing Avian Pathogenic Escherichia coli O78 LPS as a Vaccine to Prevent Airsacculitis in Chickens," Avian Diseases 43: 429-441	
		SCHÖDEL, et al. (1993) "Avirulent Salmonella expressing hybrid hepatitis B virus core/pre-S genes for oral vaccination," Vaccine 11: 143-148	
		SCHÖDEL, et al. (1994) "Development of Recombinant Salmonellae Expressing Hybrid Hepatitis B Virus Core Particles as Candidate Oral Vaccines," Brown F(ed): Recombinant Vectors in Vaccine Development. Dev. Biol. Stand. Basel, Karger 82: 151-158	
		SCHWAN, et al. (2000) "Differential Bacterial Survival, Replication, and Apoptosis-Inducing Ability of Salmonella Serovars within Human and Murine Macrophages," Infect. Immun. 68: 1005-1013	
		SHATA, et al. (2000) "Recent advances with recombinant bacterial vaccine vectors," Mol. Med. Today 6: 66-70	
		SINHA, et al. (1997) "Salmonella typhimurium aroA, htrA, and aroD htrA Mutants Cause Progressive Infections in Athymic (nu/nu) BALB/c Mice," Infect. Immun. 65: 1566-1569	
		SIRARD, et al. (1999) "Live attenuated Salmonella: a paradigm of mucosal vaccines," Immunol. Rev. 171: 5-26	
		SMITH, et al. (1984) "Aromatic-dependent Salmonella dublin as a parenteral modified live vaccine for calves," Am. J. Vet. Res. 45: 2231-2235	
		SMITH, et al. (1993) "Vaccination of calves with orally administered aromatic-dependent Salmonella dublin," Am. J. Vet. Res. 54: 1249-1255	

Examiner Signature:		Date Considered	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

**INFORMATION DISCLOSURE
STATEMENT LIST**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		SOO, et al. (1998) "Genetic Control of Immune Response to Recombinant Antigens Carried by an Attenuated Salmonella typhimurium Vaccine Strain: Nramp1 Influences T-Helper Subset Responses and Protection against Leishmanial Challenge," Infect. Immun. 66: 1910-1917	
		SPRENG, et al. (200) "Salmonella vaccines secreting measles virus epitopes induce protective immune responses against measles virus encephalitis," Microbes Infect. 2: 1687-1692	
		STEIN, et al. (1996) "Identification of a Salmonella virulence gene required for formation of filamentous structures containing lysosomal membrane glycoproteins within epithelial cells," Mol. Microbiol. 20: 151-164	
		STOCKER (2000) "Aromatic-dependent Salmonella as anti-bacterial vaccines and as presenters of heterologous antigens or of DNA encoding them," J. Biotechnol. 83: 45-50	
		STOCKER (1990) "Aromatic-Dependent Salmonella as Live Vaccine Presenters of Foreign Epitopes as Inserts in Flagellin," Res. Microbiol. 141: 787-796	
		STOCKER (1988) "Auxotrophic Salmonella typhi as live vaccine," Vaccine 6: 141-145	
		SVENSON and LINDBERG (1983) "Artificial Salmonella Vaccines," Prog. Allergy 33: 120-143	
		SYDENHAM, et al. (2000) "Salmonella enterica Serovar Typhimurium surA Mutants Are Attenuated and Effective Live Oral Vaccines," Infect. Immun. 68: 1109-1115	
		SZTEIN, et al. (1994) "Cytokine Production Patterns and Lymphoproliferative Responses in Volunteers Orally Immunized with Attenuated Vaccine Strains of Salmonella typhi," J. Infect. Disease 170: 1508-1517	

Examiner Signature:		Date Considered	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office; P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		TACKET, et al. (2000) "Phase 2 Clinical Trial of Attenuated Salmonella enterica Serovar Typhi Oral Live Vector Vaccine CVD 908-htrA in U.S. Volunteers," Infect. Immun. 68: 1196-1201	
		TACKET, et al. (2000) "Safety and Immune Responses to Attenuated Salmonella enterica Serovar Typhi Oral Live Vector Vaccines Expressing Tetanus Toxin Fragment C," Clin. Immunol. 97: 146-153	
		TACKET, et al. (1997) "Safety of Live Oral Salmonella typhi Vaccine Strains with Deletions in htrA and aroC aroD and Immune Response in Humans," Infect. Immun. 65: 452-456	
		TACKET, et al. (1992) "Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain," Vaccine 10: 443-446	
		TACKET, et al. (1992) "Comparison of the Safety and Immunogenicity of ΔaroC ΔaroD and Δcya Δcrp Salmonella typhi Strains in Adult Volunteers," Infect. Immun. 60: 536-541	
		TACKET, et al. (1991) "Lack of Immune response to the Vi Component of a Vi-Positive Variant of Salmonella typhi Live Oral Vaccine Strain Ty21a in Human Studies," J. Infect. Disease 163: 901-904	
		TACKET, et al. (1988) "Persistence of antibody titres three years after vaccination with Vi polysaccharide vaccine against typhoid fever," Vaccine 6: 307-308	
		TACKET, et al. (1986) "Safety and Immunogenicity of Two Salmonella typhi Vi Capsular Polysaccharide Vaccines," J. Infect. Disease 154: 342-345	
		TAGLIABUE (1989) "Immune Response to Oral Salmonella Vaccines," Curr. Topics Microbiol. Immunol. 146: 225-231	

Examiner Signature:	Date Considered
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		TANG, et al. (2001) "Identification of bacterial genes required for in-vivo survival," J. Pharm. Pharmacol. 53: 1575-1579	
		TITE, et al. (1991) "The Involvement of Tumor Necrosis Factor in Immunity to Salmonella Infection," J. Immunol. 147: 3161-3164	
		TRAMONT, et al. (1984) "Safety and Antigenicity of Typhoid-Shigella sonnei Vaccine (Strain 5076-1C)," J. Infect. Disease 149: 133-136	
		TURNER, et al. (1993) "Salmonella typhimurium ΔaroA ΔaroD Mutants Expressing a Foreign Recombinant Protein Induce Specific Major Histocompatibility Complex Class I-Restricted Cytotoxic T Lymphocytes in Mice," Infect. Immun. 61: 5374-5380	
		UCHIYA, et al. (1999) "A Salmonella virulence protein that inhibits cellular trafficking," EMBO J. 18: 3924-3933	
		URASHIMA, et al. (2000) "An oral CD40 ligand gene therapy against lymphoma using attenuated Salmonella typhimurium," Blood 95: 1258-1263	
		VALDIVIA and FALKOW (1996) "Bacterial genetics by flow cytometry: rapid isolation of Salmonella typhimurium acid-inducible promoters by differential fluorescence induction," Mol. Microbiol. 22: 367-378	
		VAN DISSEL, et al. (1995) "S. Typhi Vaccine Strain Ty21a Can Cause a Generalized Infection in Whole Body-Irradiated But Not in Hydrocortisone-Treated Mice," Scand. J. Immunol. 41: 457-461	
		VAN VELKINBURGH and GUNN (1999) "PhoP-PhoQ-Regulated Loci Are Required for Enhanced Bile Resistance in Salmonella spp.," Infect. Immun. 67: 1614-1622	

Examiner Signature:	Date Considered
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		VANCOTT, et al. (1998) "Regulation of host immune responses by modification of Salmonella virulence genes," Nat. Med. 4: 1247-1252	
		VANCOTT, et al. (1996) "Regulation of Mucosal and Systemic Antibody Responses by T Helper Cell Subsets, Macrophages, and Derived Cytokines Following Oral Immunization with Live Recombinant Salmonella," J. Immunol. 1504: 1514	
		VAZQUEZ-TORRES, et al. (2000) "Salmonella Pathogenicity Island 2-Dependent Evasion of the Phagocyte NADPH Oxidase," Science 287: 1655-1658	
		VÉSCOVI, et al. (1996) "MG2+ as an Extracellular Signal: Environmental Regulation of Salmonella Virulence," Cell 84: 165-174	
		VILLARREAL, et al. (1992) "Proliferative and T-cell specific interleukin (IL-2/IL-4) production responses in spleen cells from mice vaccinated with aroA live attenuated Salmonella vaccines," Microbial Pathogen. 13: 305-315	
		VIRET, et al. (1999) "Mucosal and Systemic Immune Responses in Humans after Primary and Booster Immunizations with Orally Administered Invasive and Noninvasive Live Attenuated Bacteria," Infect. Immun. 67: 3680-3685	
		VIRLOGEUX, et al. (1996) "Characterization of the rcsA and rcsB Genes from Salmonella typhi: rcsB through tviA Is Involved in Regulation of Vi Antigen Synthesis," J. Bacteriol. 178: 1691-1698	
		VIRLOGEUX, et al. (1995) "Role of the viaB locus in synthesis, transport and expression of Salmonella typhi Vi antigen," Microbiol. 141: 3039-3047	
		WAHDAN, et al. (1982) "A Controlled Field Trial of Live Salmonella typhi Strain Ty 21a Oral Vaccine Against Typhoid: Three-Year Results," J. Infect. Dis. 145: 292-295	

Examiner Signature:

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		WAHDAN, et al. (1980) "A controlled field trial of live oral typhoid vaccine Ty21a," Bull. World Health Org. 58: 469-474	
		WALLIS (2001) "Salmonella Pathogenesis and Immunity: We Need Effective Multivalent Vaccines," Vet. J. 161: 104-106	
		WALLIS and GALYOV (2000) "Molecular basis of Salmonella-induced enteritis," Mol. Microbiol. 36: 997-1005	
		WANG, et al. (2000) "Constitutive Expression of the Vi Polysaccharide Capsular Antigen in Attenuated Salmonella enterica Serovar Typhi Oral Vaccine Strain CVD 909," Infect. Immun. 68: 4647-4652	
		WARD, et al. (1999) "Immunogenicity of a Salmonella typhimurium aroA aroD Vaccine Expressing a Nontoxic Domain of Clostridium difficile Toxin A," Infect. Immun. 67: 2145-2152	
		WEDEMEYER, et al. (2001) "Oral Immunization With HCV-NS3-Transformed Salmonella: Induction of HCV-Specific CTL in a Transgenic Mouse Model," Gastroenterology 121: 1158-1166	
		WEINSTEIN, et al. (1998) "Differential Early Interactions between Salmonella enterica Serovar Typhi and Two Other Pathogenic Salmonella Serovars with Intestinal Epithelial Cells," Infect. Immun. 66: 2310-2318	
		WEINSTEIN, et al. (1997) "Salmonella typhi Stimulation of Human Intestinal Epithelial Cells Induces Secretion of Epithelial Cell-Derived Interleukin-6," Infect. Immun. 65: 395-404	
		WEINTRAUB, et al. (1997) "Role of $\alpha\beta$ and $\gamma\delta$ T Cells in the Host Response to Salmonella Infection as DEMonstrated in T-Cell-Receptor-Deficient Mice of Defined Ity Genotypes," Infect. Immun. 65: 2306-2312	

Examiner Signature:

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.); date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		WHITE, et al. (1999) "High efficiency gene replacement in Salmonella enteritidis chimeric fimbrins containing a T-cell epitope from Leishmania major," Vaccine 17: 2150-2161	
		WONG, et al. (1974) "Vi Antigen from Salmonella typhosa and Immunity Against Typhoid Fever," Infect. Immun. 9: 348-353	
		WOO, et al. (2001) "Unique immunogenicity of hepatitis B virus DNA vaccine presented by live attenuated Salmonella typhimurium," Vaccine 19: 2945-2954	
		WU, et al. (2000) "Construction and immunogenicity in mice of attenuated Salmonella typhi expressing Plasmodium falciparum merozoite surface protein 1 (MSP-1) fused to tetanus toxin fragment C," J. Biotechnol. 83: 125-135	
		WÜTHRICH, et al. (1985) "Typhusepidemiologie in der Schweiz 1980-1983," Schweiz. med. Wschr. 115: 1714-1720	
		WYANT, et al. (1999) "Salmonella typhi Flagella Are Potent Inducers of Proinflammatory Cytokine Secretion by Human Monocytes," Infect. Immun. 67: 3619-3624	
		ZHANG, et al. (1999) "Protection and immune responses induced by attenuated Salmonella typhimurium UK-1 strains," Microbial Pathogen. 26: 121-130	
		ZHOu, et al. (1999) "An invasion-associated Salmonella protein modulates the actin-bundling activity of plactin," Proc. Natl. Acad. Sci. USA 96: 10176-10181	
		CURTISS, et al. (1994) "Recombinant Salmonella vectors in vaccine development" Dev. Biol. Stand. 82:23-33	

Examiner Signature:		Date Considered	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

Application Number	10/763,883
Filing Date	January 23, 2004
First Named Inventor	Michael HENSEL
Art Unit	1645
Examiner Name	Khatol S. Shahnan
Attorney Docket Number	EMER-003/02US

NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		GALEN et al. (1997) "A murine model of intranasal immunization to assess the immunogenicity of attenuated <i>Salmonella typhi</i> live vector vaccines in stimulating serum antibody responses to expressed foreign antigens," Vaccine, 15:700-708	
		HORMAECHE, (1979) "Genetics of natural resistance to salmonellae in mice," Immunology, 37:319-327	
		JONES, et al. (1991) "Oral vaccination of calves against experimental salmonellosis using a double <i>aro</i> mutant of <i>Salmonella typhimurium</i> ," Vaccine, 9:29-34	
		JONES-CARSON et al. (2007) "Systemic CD8 T cell memory response to a <i>Salmonella</i> pathogenicity island 2 effector is restricted to <i>Salmonella enterica</i> encountered in the gastrointestinal mucosa," Infect. Immun. 75:2708-2716	
		CHENOWETH et al. (1990) "Efficacy of ampicillin versus trimethoprim-sulfamethoxazole in a mouse model of lethal enterococcal peritonitis," Antimicrob. Agents Chemother. 34:1800-1802	
		KOHLER, et al. (1998) "Oral immunization with recombinant <i>Salmonella typhimurium</i> expressing a cloned porphyromonas gingivalis hemagglutinin: effect of bovine on mucosal systemic and immunoglobulin G subclass response," Oral Microbiol. Immunol. 13:81-88. ABSTRACT ONLY	
		O'CALLAGHAN, et al. (1990) "Immunogenicity of foreign peptide epitopes expressed in bacterial envelope proteins," Res. Microbiol. 141:963-969 ABSTRACT ONLY	
		SCHODEL, et al. (1996) "Hybrid hepatitis B virus core antigen as a vaccine carrier moiety II. Expression in avirulent <i>Salmonella</i> spp. for mucosal immunization," Adv. Exp. Med. Biol. 397:15-21. ABSTRACT ONLY	

Examiner Signature:		Date Considered	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.